Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| ULCT123456 | Registry Identifier | ULCT123456 | |
| ULCT123456 | Registry Identifier | Ministry of Health | |
| HCC8/T2A/443111 | Registry Identifier | HCC8/T2A/443 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
In the last decade, the prevalence of malaria has been escalating at an alarming rate, especially in Africa. An estimated 300 to 500 million cases each year cause 1.5 to 2.7 million deaths, more than 90% occur in children under 5 years of age in Africa (WHO 1995). Malaria is Africa's leading cause of under-five mortality (20%) and constitutes 10% of the continent's overall disease burden. It accounts for 40% of public health expenditure, 30-50% of inpatient admissions, and up to 50% of outpatient visits in areas with high malaria transmission. Antioxidant micronutrients have immunomodulatory role and may have suppressive activity.
The pathogenesis of plasmodial infection hinges on intracellular invasion of host erythrocyte and hepatocyte with possible generation of free radicals that may contribute to cellular membrane damage. This will make uninfected erythrocyte and hepatocyte to be more susceptible to merozoite invasion. Zinc and Selenium has immunomodulatory properties. They enhance cell-mediated immune response in malaria infection. This may help to adequately suppress schizont maturation and inhibit the release of merozoites. However, it is possible that they have a direct chemosuppressive or blood schizonticidal effect. The following research questions emanated from this hypothesis;
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| COHORT A= Amodiaquine + Artesunate | Active Comparator | Amodiaquine will be administered orally at 10mg/kg daily for 3days. Artesunate 50mg will be administered orally daily for 3days.For subjects >6months< 1 years 4mg/kg daily for 3 days |
|
| cohort B= Lumefantrine +Artemether | Active Comparator | Artemether 20mg/Lumefantrine 120mg fixed combination administered daily for 3 days |
|
| cohort C = Artesunate + vitamin A | Experimental | Artesunate 50mg daily for 4days. if >6 months< 1 year 4mg/kg daily for 4days + Vitamin A 5000IU daily for 4days if < 1 year and 10,000IU daily for 4days if > 1 year respectively |
|
| Artesunate, vitamin E oral administration | Experimental | Artesunate 50mg daily for 4 days.if >6 months< 1 year 4mg/kg daily for 4 days + vitamin E 100mg daily administered orally to the experimental group 4 days. |
|
| cohort E will be given Artesunate and Zinc orally | Experimental | cohort E will be given Artesunate 50mg daily for 4 days. if > 6 months< 1 year 4mg/kg daily for 4 days + zinc gluconate 50mg orally daily for 4 days. if < 1 year 25 mg daily for 4 days |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Amodiaquine + Artesunate | Drug | Intervention:the intervention in this group involves the use of standard antimalarial therapy for uncomplicated malaria based on WHO recommendation. artemisin based combination therapy will be used. amodiaquine will be administered via the oral route at a dose of 10mg/kg daily while artesunate will be administered orally at Artesunate 100mg stat, 50mg 8hrs later and 50mg bd x 3days |
| Measure | Description | Time Frame |
|---|---|---|
| 7-day cure rate | 7-day Cure rate will be defined as initial and sustained parasite and symptom clearance with no increase in asexual parasitemia 48 h after the initiation of treatment and the absence of microscopically detected asexual parasitemia within 120 h of the commencement of treatment until day 7 | 4 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| 28-day cure rate. | the number of patients with clinical and parasitological cure by day 28 divided by the total number of patients who could be evaluated (per protocol population). | 4 weeks |
Not provided
Inclusion Criteria:
Exclusion Criteria:
adequate antimalarial treatment within the previous 7 days
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Osede Ignis Iribhogbe, MB.BS, M.Sc | Department of Pharmacology and Therapeutics, College of Medicine, Ambrose Alli University, Ekpoma | Principal Investigator |
| Ibrahim Oreagba, B.Pharm, M.Sc, Ph.D | Deparment of Pharmacology, College of Medicine, University of Lagos, Nigeria | Study Director |
| Elizabeth O. Agbaje, B.Sc, M.Sc, MPhil, Ph.D | Department of Pharmacology, College of Medicine University of Lagos, Nigeria | Study Chair |
| Prof. Onyebiguwa Patrick NMORSI, PhD, MD | Dean, Faculty of Natural Sciences Ambrose Alli University Ekpoma | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Central Primary Health Centre, Ukpenu, Road, Ekpoma. | Ekpoma | Edo | +234 | Nigeria | ||
| Faithdome Medical Centre, Ekpoma. |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 11431296 | Background | Muller O, Becher H, van Zweeden AB, Ye Y, Diallo DA, Konate AT, Gbangou A, Kouyate B, Garenne M. Effect of zinc supplementation on malaria and other causes of morbidity in west African children: randomised double blind placebo controlled trial. BMJ. 2001 Jun 30;322(7302):1567. doi: 10.1136/bmj.322.7302.1567. |
| Label | URL |
|---|---|
| chemoprophylactic effect of vitamin C in malaria | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| cohort F= Artesunate and selenium will be given orally | Experimental | Artesunate 50mg daily for 4 days. if > 6 months< 1 year 4mg/kg daily for 4 days + selenium 100ug daily for 4 days. if < 1 year 50ug daily for 4 days. |
|
| cohort G = Amodiaqiune and Vitamin A will be given orally | Experimental | Amodiaquine 10mg/kg daily for 3 days + vitamin A 5000iu daily for 4 days if < 1 year. 10,000 IU daily for 4 days if > 1 year. |
|
| cohort H = amodiaquine and vitamin E administerd orally | Experimental | Amodiaquine 10mg/kg daily for 4 days + vitamin E 100 mg daily for 4 days |
|
| cohort I = Amodiaquine and Zinc will be given orally | Experimental | Amodiaquine 10mg/kg daily for 4 days + zinc 50mg daily 4 days. if < 1 year 25 mg daily for 4 days. |
|
| Cohort J = amodiaquine and selenium will be given orally | Experimental | Amodiaquine 10mg/kg daily for 4 days + selenium 100ug daily for 4 days if > 1 year. 50ug daily for 4 days if < 1 year. |
|
| K= Artesunate+ vitamin A + vitamin E | Experimental | Tab Artesunate 50mg orally dly x 4 days + Vitamin A, 5000IU orally, dly x 4 days if ≤ 1yr. 10,000IU orally dly x 4days if > 1 yr + vitamin E 100 mg orally dly for 4 days |
|
| L = Artesunate+ Vitamin A + Zinc | Experimental | Tab Artesunate 50 mg daily for 4 days. Vitamin A 5OOOIU daily for 4 days if < 1 year. 10,000IU daily for 4 days if > 1 year. All administered orally. |
|
| M = Artesunate+ Vitamin A + selenium | Experimental | Artesunate 50 mg orally, daily for 4 days. Vitamin A 5000IU orally daily for 4 days if < 1 year. 10,000IU orally daily for 4 days if > 1 year. |
|
| N = Artesunate + Vitamin E + Zinc | Experimental | Artesunate 50mg daily for 4 days. vitamin E 100mg daily for 4 days. Zinc 50 mg daily for 4 days if > 1 year. 25 mg daily for 4 days if < 1 year. |
|
| O = Artesunate+ Vitamin E + Selenium | Experimental | Tab Artesunate 50 mg orally daily for 4 days. Vitamin E 100 mg orally daily for 4 days. Tab selenium 100 ug orally daily for 4 days if > 1 year. 50 ug orally daily for 4 days if < 1 year. |
|
|
| Amodiaquine + Artesunate | Drug | Intervention:the intervention in this group involves the use of standard antimalarial therapy for uncomplicated malaria based on WHO recommendation. artemisinin based combination therapy will be used. amodiaquine will be administered via the oral route at a dose of 10mg/kg daily while artesunate will be administered orally at 100mg stat, 5omg 8hrs later and 50mg 12hrly for 3 days |
|
| Lumefantrine + Artemether | Drug | Lumefantrine and artemether combination will be administered orally at a dose of 120/20mg daily for 3days |
|
| Artesunate + vitamin A | Dietary Supplement | Artesunate will be administered orally at a dose of 100mg stat then 50 mg 8hrs later and 50mg 12hrly for 3days. vitamin A will be administered orally at a dose of 2000IU daily for 3 days |
|
| Artesunate + vitamin E | Dietary Supplement | Artesunate will be administered orally at 100mg stat, then 50mg 8hrs after and 50mg 12hrly for 3 days. Vitamin E will be administered orally at 100mg dly for 3 days. |
|
| Artesunate + Zinc | Dietary Supplement | Artesunate will be administered orally at a dose of 100mg stat then 50mg 8hrs after and 50mg 12mg 12hrly for 3 days. Zinc gluconate will be administered orally at a dose of 50mg dly for 4 days |
|
| Artesunate + selenium | Dietary Supplement | Artesunate will be administered orally at 100mg stat and 8hrs later 50mg. then 50mg 12hrly for 3 days. selenium will be administered orally at a dose of 100ug dly for 4 days |
|
| Amodiaquine + vitamin A | Dietary Supplement | Amodiaquine will be administered orally at a dose of 10mg/kg dly for 3days. Vitamin A will be administered orally dly at a dose of 2000IU for 4 days |
|
| Amodiaquine + Vitamin E | Dietary Supplement | Amodiaquine will be administered orally at a dose of 10mg/kg dly for 3days. vitamin E will be administered orally at a dose 100mg daily for 4 days |
|
| Amodiaquine + Zinc | Dietary Supplement | Amodiaquine will be administered orally at a dose of 10mg/kg dly for 3days. Zinc gluconate will be administered orally at a dose of 50mg dly for 4 days. |
|
| Amodiaquine + Selenium | Dietary Supplement | Amodiaquine will be administered orally at a dose of 10mg/kg daily for 3days. Selenium will be administered orally at a dose of 100ug daily for 4 days if > 1year. 50ug daily for 4 days if < 1 year. |
|
| Artesunate + vitamin A + vitamin E | Dietary Supplement | Tab Artesunate 50mg orally daily for 4 days. Vitamin A, 5000IU orally daily for 4days if < 1 year. 10,000 IU orally daily for 4 days if > 1 year. |
|
| Artesunate + Vitamin A + Zinc | Dietary Supplement | Tab Artesunate 50 mg daily for 4 days. Vitamin A 5OOOIU daily for 4 days if < 1 year. 10,000IU daily for 4 days if > 1 year. All administered orally. |
|
| Artesunate + Vitamin A + Selenium | Dietary Supplement | Tab Artesunate 50 mg orally, daily for 4 days. Vitamin A 5000IU orally daily for 4 days if < 1 year. 10,000IU orally daily for 4 days if > 1 year. |
|
| Artesunate + Vitamin E + Selenium | Dietary Supplement | Tab Artesunate 50 mg orally daily for 4 days. Vitamin E 100 mg orally daily for 4 days. Tab selenium 100 ug orally daily for 4 days if > 1 year. 50 ug orally daily for 4 days if < 1 year. |
|
| Artesunate + Vitamin E + Zinc | Dietary Supplement | Tab Artesunate administered orally at 50 mg daily for 4 days. Vitamin E 100 mg orally daily for 4 days. Tab Zinc 50 mg orally daily for 4 days if < 1 year. 25 mg orally daily for 4 days if > 1 year. |
|
| Ekpoma |
| Esan West, Edo State |
| +234 |
| Nigeria |
| ID | Term |
|---|---|
| D008288 | Malaria |
| ID | Term |
|---|---|
| D011528 | Protozoan Infections |
| D010272 | Parasitic Diseases |
| D007239 | Infections |
| D000096724 | Mosquito-Borne Diseases |
| D000079426 | Vector Borne Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C515299 | amodiaquine, artesunate drug combination |
| D000077611 | Artemether, Lumefantrine Drug Combination |
| D000077332 | Artesunate |
| D014801 | Vitamin A |
| D014810 | Vitamin E |
| D015032 | Zinc |
| D012643 | Selenium |
| D000655 | Amodiaquine |
| ID | Term |
|---|---|
| D000077549 | Artemether |
| D037621 | Artemisinins |
| D017382 | Reactive Oxygen Species |
| D005609 | Free Radicals |
| D007287 | Inorganic Chemicals |
| D009930 | Organic Chemicals |
| D000078102 | Lumefantrine |
| D005449 | Fluorenes |
| D011084 | Polycyclic Aromatic Hydrocarbons |
| D006841 | Hydrocarbons, Aromatic |
| D006844 | Hydrocarbons, Cyclic |
| D006838 | Hydrocarbons |
| D012717 | Sesquiterpenes |
| D013729 | Terpenes |
| D011083 | Polycyclic Compounds |
| D004338 | Drug Combinations |
| D004364 | Pharmaceutical Preparations |
| D012176 | Retinoids |
| D002338 | Carotenoids |
| D011090 | Polyenes |
| D000475 | Alkenes |
| D006839 | Hydrocarbons, Acyclic |
| D053138 | Cyclohexenes |
| D003510 | Cyclohexanes |
| D003516 | Cycloparaffins |
| D006840 | Hydrocarbons, Alicyclic |
| D004224 | Diterpenes |
| D010860 | Pigments, Biological |
| D001685 | Biological Factors |
| D001578 | Benzopyrans |
| D011714 | Pyrans |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
| D006574 | Heterocyclic Compounds, 2-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
| D019216 | Metals, Heavy |
| D004602 | Elements |
| D028561 | Transition Elements |
| D008670 | Metals |
| D018011 | Chalcogens |
| D008903 | Minerals |
| D000634 | Aminoquinolines |
| D011804 | Quinolines |
Not provided
Not provided